Effect of isradipine on 24-h blood pressure profile demonstrated by repeated monitoring.
The antihypertensive effect of isradipine was assessed by repeated 24-h ambulatory blood pressure monitoring. Using an SPS device (Sandoz Pharma, Basel, Switzerland), monitoring was carried out in 10 male patients with mild essential hypertension (1) after a placebo period, (2) after six months, and (3) after 12 to 13 months of treatment with isradipine (average dose 2.5 mg twice daily). Mean 24-h blood pressure decreased significantly after both periods 2 and 3 (from 148/93 mm Hg to 137/87 and 130/85 mm Hg, respectively). The total number of hypertensive systolic and diastolic blood pressure values also decreased. The normal circadian blood pressure curve was preserved, showing the reduction throughout the 24-h period, and the early morning rise in blood pressure was markedly blunted. These results indicate that isradipine has a favorable effect on the 24-h blood pressure profile that persisted throughout six and 12 months of antihypertensive therapy.
Cihák
R
R
Department of Cardiology, Postgraduate Medical and Pharmaceutical Institute, Prague, Czechoslovakia.
Widimský
J
J
Lefflerová
K
K
Janský
P
P
D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects*; D001795:Blood Pressure Determination / Q000379:methods; D002121:Calcium Channel Blockers / Q000494:pharmacology* / Q000592:standards / Q000627:therapeutic use; D002940:Circadian Rhythm; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology; D017275:Isradipine; D008297:Male; D008875:Middle Aged; D011725:Pyridines / Q000494:pharmacology* / Q000592:standards / Q000627:therapeutic use; D013997:Time Factors
D002121:Calcium Channel Blockers; D011725:Pyridines; D017275:Isradipine